Comparative Pharmacology
Head-to-head clinical analysis: NORGESIC versus RALDESY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORGESIC versus RALDESY.
NORGESIC vs RALDESY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
NORGESIC is a combination of orphenadrine citrate, aspirin, and caffeine. Orphenadrine is a centrally acting muscle relaxant with anticholinergic properties; its exact mechanism is not fully understood, but it may act via central atropine-like effects and inhibition of reuptake of norepinephrine and serotonin. Aspirin inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, leading to analgesic, antipyretic, and anti-inflammatory effects. Caffeine is a central nervous system stimulant that may enhance analgesia via adenosine receptor antagonism.
Selective beta-3 adrenergic receptor agonist; relaxes detrusor smooth muscle during storage phase of urinary bladder fill cycle, increasing bladder capacity and reducing urgency.
1-2 tablets orally 2-4 times daily. Each tablet contains orphenadrine citrate 100 mg and acetaminophen 325 mg.
Intravenous: 1 mg/kg every 8 hours; maximum single dose 100 mg.
None Documented
None Documented
Terminal elimination half-life is 2–4 hours; clinical multiple dosing may require 4–6 hour intervals
4-6 hours in adults; prolonged to 8-12 hours in elderly or renal impairment (CrCl <30 mL/min)
Primarily renal (70% as unchanged drug and metabolites; 10% as unchanged) and biliary (30%)
Primarily renal (85-90%) with 60% unchanged; biliary/fecal (10-15%)
Category C
Category C
Muscle Relaxant
Muscle Relaxant